SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lake AE, Rains JC, Penzien DB, Lipchik GL. Headache and psychiatric comorbidity: Historical context, clinical implications, and research relevance. Headache. 2005;45:493-506.
  • 2
    Maizels M, Smitherman TA, Penzien DB. A review of screening tools for psychiatric comorbidity in headache patients. Headache. 2006;46(suppl 3):S98-S109.
  • 3
    Lipchik GL, Smitherman TA, Penzien DB, Holroyd KA. Basic principles and techniques of cognitive-behavioral therapies for comorbid psychiatric symtoms among headache patients. Headache. 2006;46(suppl 3):S119-S132.
  • 4
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington : American Psychiatric Publishing; 2000.
  • 5
    Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006;46(suppl 3):S76-S87.
  • 6
    Schatzberg AF, Cole JO, DeBattista C. Manual of Psychopharmacology, 5th ed. Washington : American Psychiatric Publishing; 2005:38.
  • 7
    Boland BJ, Keller MB. Treatment of depression. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:847-864.
  • 8
    American Psychiatric Association Steering Committee on Practice Guidelines: Treating major depressive disorder. Quick Reference to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2002. Washington : American Psychiatric Publishing; 2002:99-119.
  • 9
    Thase ME. Antidepressant options: Venlafaxine in perspective. J Clin Psychopharmacol. 1996;16(3 suppl 2):10S-19S.
  • 10
    Thase ME, Sloan DME. Venlafaxine. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:349-360.
  • 11
    Loder E, Biondi D. General principles of migraine management: The changing role of prevention. Headache. 2005;45(suppl 1):S33-S47.
  • 12
    Nelson JC. Tricyclic and tetracyclic drugs. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:207-230.
  • 13
    Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000;40:572-580.
  • 14
    Suleyman SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144-152.
  • 15
    Levy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol. 2003;18:301-303.
  • 16
    Greden JF. Duloxetine and milnacepran. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:361-370.
  • 17
    Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: An open-label study. Headache. 2001:41:465-474.
  • 18
    Bendtsen L, Jeansen R, Olesen: A non-selective (amitriptyline) but not a selective (citalopram) serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type head pain. J Neurol Neurosurg Psych. 1996;61:285-290.
  • 19
    Saper JR, Silberstein SD, Lake AE III, Winters ME. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994;34:587-589.
  • 20
    Landy S, McGinnis J, Curlin D, Laizure C. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999;39:28-32.
  • 21
    Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(suppl 8):5-22.
  • 22
    Thase EA, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
  • 23
    American Psychiatric Association Steering Committee on Practice Guidelines: Treating bipolar disorder. Quick Reference to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric disorders: Compendium 2002. Washington : American Psychiatric Publishing; 2002:121-141.
  • 24
    Keck PE, McElroy SL. Treatment of bipolar disorder. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:865-883.
  • 25
    Siow HC, Young WB, Silberstein SD. Neuroleptics in headache. Headache. 2005;45:358-371.
  • 26
    Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002;42:515-518.
  • 27
    Rozen TD. Olanzapine as an abortive agent for cluster headaches. Headache. 2001;41:813-816.
  • 28
    Manzoni GC, Bono G. Lithium carbonate in cluster headache: Assessment of its short- and long-term therapeutic efficacy. Cephalgia. 1983;3:109-114.
  • 29
    McElroy SL, Keck PE. Topiramate. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:627-636.
  • 30
    Mathew NT, Rapoport A, Saper J, et al Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119-128.
  • 31
    Frye MA. Gabapentin. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:607-636.
  • 32
    Davidson JRT, Connor KM. Treatment of anxiety disorders. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004:913-934.
  • 33
    Lee ST, Park JH, Kim M. Efficacy of the 5-HT-1A agonist, buspirone hydrochloride, in migraineurs with anxiety: A randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache. 2005;45:1004-1011.
  • 34
    Ninan PT, Muntasser S. Buspirone and gepirone. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004: 391-404.
  • 35
    Adetunji B, Mathews M, Williams A, et al Use of antipsychotics in the treatment of post-traumatic stress disorder. Psychiatry. 2005;2:43-47
  • 36
  • 37
    Delva NJ, Horgan SA, Hawken ER. Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors. Headache. 2000;40:248-251.
  • 38
    Ninan PT, Muntasser S. Buspirone and gepirone. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004: 391-404.
  • 39
    Ketter TA, Wang PW, Post RM. Carbamazepine and oxcarbazepine. In: SchatzbergAF, NemeroffCB, eds. American Psychiatric Publishing Textbook of Psychopharmacology, 3rd ed. Washington : American Psychiatric Publishing; 2004: 581-606.
  • 40
    Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy. 24:621-629.